Want to join the conversation?
British pharmaceutical group $GSK said it would buy the portfolio of experimental HIV drugs from its U.S. rival $BMY for a total of $1.46Bil in two transactions. $GSK expects to complete both the transactions during the first half of FY16. The deal is expected to strengthen $GSK's global HIV business ViiV Healthcare's control in the HIV market.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.